GAIN Trial: Phase 2/3 Study of COR388 in Subjects With Alzheimer's Disease
Status:
Active, not recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled study that will assess the efficacy,
safety, and tolerability of 2 dose levels of COR388 in subjects with a clinical diagnosis of
mild to moderate AD dementia.